SaxoCell Cluster
- Company typePrivate
- Founded2020
- HeadquartersLeipzig, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
SaxoCell Cluster firmographics
Firmographics- Name
- SaxoCell Cluster
- Legal name
- SaxoCell e.V.
- Website
- https://saxocell.de
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SaxoCell Cluster industry classification
Industry- Product category
- Cell and Gene Therapy Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), Cell Therapy Developers (Autologous) (HLAAABAA)
Keywords
Where SaxoCell Cluster is headquartered
LocationHeadquarters
- HQ city
- Leipzig
- HQ country
- Germany
- HQ region
- Europe
Markets served
SaxoCell Cluster business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Distribution channels4 records
Marketing channels7 records
SaxoCell Cluster product offering
Product offeringCore offering
SaxoCell Cluster is a publicly funded research association (SaxoCell e.V.) that develops novel gene and cell therapeutics, so-called "living drugs," including CAR-T cell therapies, NK cell therapies, allogeneic macrophage therapies, and genome editing technologies for cancer, autoimmune, and inflammatory diseases. The cluster coordinates seven research projects and one management project, combining academic institutions, university hospitals, and biotech partners in Saxony, Germany, to translate cell and gene therapy discoveries from bench to bedside, with emphasis on automated manufacturing and socially acceptable costs.
Product overview
SaxoCell is a research and innovation cluster focused on developing novel gene and cell therapeutics, so-called 'living drugs'. The cluster operates as a platform combining multiple therapeutic technologies and programs including CAR-T cell therapies (UniK-Tackle, UniK-Tame), MSC-based therapeutics (DESACELL®), NK cell therapies, and genome editing technologies (designer recombinases). The portfolio includes advanced therapy medicinal products like Palintra® for GvHD prevention, technology platforms like CAR FINDER for CAR candidate identification, and various cell therapy programs targeting cancer, autoimmune diseases, and inflammatory conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- DESACELL®
- UniK-Tackle
- UniK-Tame
- Palintra®
- CAR FINDER
- NK Cell Therapy Platform
- Designer Recombinase Technology
Quantifiable outcome
- Patient achieved complete remission from advanced malignant melanoma after experimental cell therapy at University Hospital Dresden
- +2 more outcomes
Companies that use SaxoCell Cluster
Customer profileSegments4 records
Ideal customer profiles4 records
SaxoCell Cluster technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature7 records
SaxoCell Cluster partnerships and signals
Strategic signalPartnerships
26 partnerships are on record, tiered major, supporting and core.
- DKMS StemCellBank gGmbHmajorIndustry partner in UniKT and MSC-READY projects, contributing stem cell banking expertise and GMP facilities for cell therapy development.
- Seamless Therapeutics GmbHmajorBiotech partner in UniKT project contributing programmable recombinase technology for genome editing in CAR-T cell development.
- Cancilico GmbHmajorSpin-off company partner in UniKT and SB-TRACT projects developing innovative cell therapy approaches.
- T-CURX GmbHmajorCAR-T immunotherapy start-up partner in SB-TRACT project contributing to Sleeping Beauty transposon-modified T cell development.
- BioThrust GmbHmajorNK-Alliance partner with core membrane aeration technology for bioreactors, spin-off from RWTH Aachen University.
- MDTB Cells GmbHmajorIndustry partner responsible for GMP scaling and development of DESACELL therapeutic platform for MSC-based therapies.
- Miltenyi Biotec B.V. & Co. KGsupportingTechnology partner in NK-Alliance project providing cell separation and processing technologies for cell therapy development.
- CytivasupportingTechnology partner providing BioPharma Services in EMEA with focus on RNA-LNP technologies and CDMO solutions. Associated partner in SB-TRACT.
- FreseniusmajorMajor industry partner and member of SaxoCell e.V. association contributing to cell and gene therapy ecosystem development.
- FamiCord AGmajorLargest cord blood bank in Europe and member of SaxoCell e.V., contributing expertise in cord blood banking and stem cell applications.
- ProBioGen AGsupportingTechnology partner in NK-Alliance providing cell line development and bioprocessing expertise for cell therapy manufacturing.
- Wacker Chemie AGsupportingNK-Alliance partner contributing expertise in biochemical manufacturing and raw materials for cell therapy production.
- Haema AGsupportingSB-TRACT project partner providing blood banking and cell processing capabilities.
- TheryCell GmbHsupportingSB-TRACT project partner contributing to T cell therapy development and manufacturing.
- Cell.Copedia GmbHsupportingNK-Alliance partner contributing bioinformatics expertise for NK cell analysis and characterization.
- ecSeq Bioinformatics GmbHsupportingNK-Alliance partner providing bioinformatics solutions for sequencing data analysis in cell therapy research.
- German Red Cross Blood Donation Service Baden-Württemberg-HessensupportingNK-Alliance partner providing blood donor resources and expertise in blood cell processing.
- QuoData GmbHsupportingNK-Alliance partner providing data analysis and quality management solutions for cell therapy development.
- Helmholtz-Zentrum Dresden-Rossendorf (HZDR)majorResearch partner in UniKT project contributing expertise in radiopharmaceutical cancer research through Prof. Anja Feldmann.
- University Hospital Carl Gustav Carus DresdencoreCore clinical partner providing patient treatment, GMP laboratories, and clinical trial infrastructure. Prof. Martin Bornhäuser serves as cluster spokesperson.
- University Hospital LeipzigcoreCore clinical partner contributing to multiple projects including SafeTy and NK-Alliance with expertise in hematology and cell therapy.
- SEMECOsupportingAnother Cluster4Future initiative collaborating with SaxoCell on events including Fuck-Up Nights and joint presentations at conferences.
- TU Dresden (Technical University of Dresden)coreCore academic partner in SaxoCell cluster, providing research expertise in cell and gene therapy, medical systems biology, and clinical translation. Prof. Frank Buchholz serves as cluster spokesperson representing TU Dresden.
- Leipzig UniversitycoreCore academic partner contributing expertise in clinical immunology, pharmacology, and medical research. Prof. Dr. Ulrike Köhl serves as cluster spokesperson representing Leipzig.
- Fraunhofer Institute for Cell Therapy and Immunology (IZI)coreCore research partner providing expertise in cell therapy development, GMP manufacturing, and technology transfer. Prof. Dr. Ulrike Köhl is Director of Fraunhofer IZI.
- Chemnitz Hospital (Klinikum Chemnitz)coreClinical partner contributing to the SafeTy project and research activities, providing patient access and clinical expertise.
Scale indicators7 records
Recent moves2 records
SaxoCell Cluster competitors and assessment
Company assessmentDirect peers
- Miltenyi Biotec: Miltenyi Biotec is a SaxoCell technology partner that provides cell separation, processing, and manufacturing technologies for cell therapy development. It is one of the most prominent European cell and gene therapy tools and services providers and is directly comparable as a technology enabler for CAR-T, NK, and other advanced therapy workflows pursued by SaxoCell.
- Adaptimmune Therapeutics: Adaptimmune is a clinical-stage cell therapy company developing engineered TCR-T cell therapies for solid tumors, with established clinical and manufacturing infrastructure. It is directly comparable to SaxoCell's SB-TRACT (Sleeping Beauty transposon-modified TCR-T cells for solid tumours) and other T-cell receptor programs.
- Cellectis: Cellectis is a clinical-stage biopharmaceutical company developing allogeneic (universal) CAR-T cell therapies using gene editing (TALENs) — directly comparable to SaxoCell's UniKT universal allogeneic CAR-T platform and Edit-Save virus-independent genome editing programs targeting cancer and autoimmune disease.
- Allogene Therapeutics: Allogene is a clinical-stage biotechnology company pioneering allogeneic CAR-T cell therapies for oncology, with multiple programs in clinical development. It is directly comparable to SaxoCell's allogeneic CAR-T focus via UniKT and SB-TRACT, and represents the leading commercial benchmark for off-the-shelf cell therapy platforms.
- Fate Therapeutics: Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf, iPSC-derived NK cell and T-cell therapies for cancer and autoimmune disease — directly comparable to SaxoCell's NK-Alliance (ex vivo-modified NK cells), AlloMac (allogeneic macrophages), and MSC-READY programs targeting the same allogeneic, off-the-shelf cell therapy opportunity.
Emerging players
- Seamless Therapeutics: Seamless Therapeutics is a SaxoCell spin-off developing programmable recombinase technology for genome editing in CAR-T cell development. It is an emerging player emerging directly from the cluster and represents a key commercialization vehicle for cluster IP, with overlapping technology to its parent.
- T-CURX GmbH: T-CURX is a CAR-T immunotherapy start-up that is a SaxoCell partner in the SB-TRACT project, developing Sleeping Beauty transposon-modified T cells for solid tumors. It is an emerging player with direct technological and operational overlap with the cluster.
- MaxCyte: MaxCyte provides electroporation-based cell engineering and manufacturing platform technologies used by cell therapy developers including CAR-T and NK programs. It overlaps with SaxoCell's automation and cell engineering priorities across its CAR-T, NK, and macrophage programs.
- ProBioGen AG: ProBioGen is a Berlin-based contract development and manufacturing organization specializing in cell line development and bioprocessing for cell and gene therapy. It is a SaxoCell partner in NK-Alliance and provides directly comparable cell therapy manufacturing and process development capabilities.
Broad incumbents
- Cytiva: Cytiva is a global life sciences tools and bioprocessing company providing manufacturing technologies, CDMO services, and RNA-LNP capabilities to the cell and gene therapy industry. It is a SaxoCell associated partner in SB-TRACT and operates as a broad incumbent enabling advanced therapy manufacturing comparable to SaxoCell's automation goals.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
SaxoCell Cluster social profiles
Digital presenceSaxoCell Cluster financial estimates
Financial estimateRevenue estimate
Valuation estimate
SaxoCell Cluster leadership team
Management profileNumber of profiles
Profiles13 records
SaxoCell Cluster funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SaxoCell Cluster M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SaxoCell Cluster
What does SaxoCell Cluster do?
SaxoCell Cluster is a publicly funded research association (SaxoCell e.V.) that develops novel gene and cell therapeutics, so-called "living drugs," including CAR-T cell therapies, NK cell therapies, allogeneic macrophage therapies, and genome editing technologies for cancer, autoimmune, and inflammatory diseases. The cluster coordinates seven research projects and one management project, combining academic institutions, university hospitals, and biotech partners in Saxony, Germany, to translate cell and gene therapy discoveries from bench to bedside, with emphasis on automated manufacturing and socially acceptable costs.
Is SaxoCell Cluster a public or private company?
SaxoCell Cluster is a private company. It is classified as state government owned and is currently operating.
When was SaxoCell Cluster founded?
SaxoCell Cluster was founded in 2020. It employs 11 to 50 people.
Where is SaxoCell Cluster based?
SaxoCell Cluster is headquartered in Leipzig, Germany, in the Europe region.
Who are SaxoCell Cluster's main competitors?
Direct peers on record are Miltenyi Biotec, Adaptimmune Therapeutics, Cellectis, Allogene Therapeutics and Fate Therapeutics. Emerging players are Seamless Therapeutics, T-CURX GmbH, MaxCyte and ProBioGen AG. Cytiva is listed as a broad incumbent.
Does SaxoCell Cluster have an API?
No public API is recorded for SaxoCell Cluster.
What industry is SaxoCell Cluster in?
SaxoCell Cluster's product category is Cell and Gene Therapy Research. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2836.